Literature DB >> 7911877

Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin.

D R Illingworth1, D W Erkelens, U Keller, G R Thompson, M J Tikkanen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7911877     DOI： 10.1016/s0140-6736(94)92945-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  20 in total

1.  Comparison of national administrative and commercial databases to monitor expenditure and costs of statins across Europe.

Authors:  T Walley; P Folino-Gallo; U Schwabe; E Van Ganse; P Stephens
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

2.  The defined daily dose as a tool in pharmacoeconomics. Advantages and limitations.

Authors:  K W Clarke; D Gray
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

3.  Suboptimal choices and dosing of statins at start of therapy.

Authors:  Aukje K Mantel-Teeuwisse; Olaf H Klungel; Tom Schalekamp; W M Monique Verschuren; Arijan J Porsius; Anthonius de Boer
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

Review 4.  Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.

Authors:  Kari T Kivistö; Mikko Niemi
Journal:  Pharm Res       Date:  2006-12-20       Impact factor: 4.200

Review 5.  [Goals and practical implementation of lipid therapy in coronary heart disease].

Authors:  F U Beil; E Windler
Journal:  Herz       Date:  1997-06       Impact factor: 1.443

Review 6.  Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.

Authors:  G L Plosker; A J Wagstaff
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

7.  Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia.

Authors:  N Cutler; J Sramek; A Veroff; G Block; L Stauffer; C Lines
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

Review 8.  Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.

Authors:  T R Pedersen; J A Tobert
Journal:  Drug Saf       Date:  1996-01       Impact factor: 5.606

9.  Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy.

Authors:  J Larsen; A Vaccheri; M Andersen; N Montanaro; U Bergman
Journal:  Br J Clin Pharmacol       Date:  2000-05       Impact factor: 4.335

Review 10.  Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia.

Authors:  G L Plosker; D McTavish
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.